Depolarizing Blockers: Mechanism of Action

Depolarizing blockers bind to nicotinic acetylcholine receptors at the motor end plate, opening sodium channels and allowing ion entry that depolarizes the muscle membrane. Unlike acetylcholine, succinylcholine resists hydrolysis by acetylcholinesterase, remaining bound longer and causing prolonged depolarization. This persistent depolarization prevents the membrane from repolarizing, leading to phase I blockade with involuntary muscle twitching, followed by phase II blockade and complete muscle paralysis.

Succinylcholine consists of two acetylcholine molecules joined by an acetate methyl group, making it structurally different from acetylcholine. This chemical modification renders succinylcholine resistant to hydrolysis by acetylcholinesterase, the enzyme that normally breaks down acetylcholine. Because succinylcholine persists longer at the receptor, it produces prolonged depolarization and extended neuromuscular blockade lasting 5-10 minutes.

Phase I blockade occurs during initial depolarization when neurons stop firing and the motor endplate fails to repolarize immediately, causing involuntary muscle twitching. After prolonged depolarization, succinylcholine diffuses away, sodium channels close, and the membrane repolarizes. Receptors then become desensitized to acetylcholine, leading to phase II blockade, where muscles become fully paralyzed without twitching.

Depolarizing blockers have a rapid onset, usually within one minute of administration. This quick action makes them helpful for emergency airway management, endotracheal intubation, and mechanical ventilation during surgical procedures. Their fast onset combined with their brief duration of action makes them valuable for procedures requiring rapid muscle relaxation.

Cholinesterase inhibitors block the breakdown of acetylcholine, increasing acetylcholine concentration at the neuromuscular junction. With depolarizing blockers, this further enhances depolarization and prolongs blockade. This contrasts with nondepolarizing competitive neuromuscular blockers, where cholinesterase inhibitors reverse the blockade by increasing acetylcholine competition at receptors.

Depolarizing blockers are used during emergencies for airway management, endotracheal intubation, mechanical ventilation, and electroconvulsive shock therapy. Their rapid onset and short duration make them ideal for procedures requiring quick muscle relaxation. However, succinylcholine should be avoided in patients with mutated or deficient cholinesterases, as it produces prolonged blockade in these individuals.

Depolarizing blockers contain two quaternary N+ atoms that bind to nicotinic acetylcholine receptors, mimicking acetylcholine's structure and function. Succinylcholine, the most commonly used depolarizing blocker, resembles acetylcholine closely enough to activate the same receptors and open sodium channels. This structural similarity allows depolarizing blockers to act on the neuromuscular junction in the same way as the endogenous ligand.